{"entity":{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","aka":[],"tldr":"Where Charles Perou defined the PAM50 intrinsic subtypes of breast cancer; a public university centre with in-house CAR-T manufacturing.","summary":"NCI-designated since 1975 and comprehensive since 1990, UNC Lineberger is a public-university cancer centre with a statewide remit across North Carolina. Charles Perou's intrinsic subtypes and the PAM50 assay reshaped breast cancer classification; Norman Sharpless, later NCI director, worked on CDK4/6 and cellular senescence here and co-founded G1 Therapeutics. Gianpietro Dotti and Barbara Savoldo run one of the few academic in-house CAR-T programmes, and Ethan Basch's patient-reported outcome trials changed how symptoms are monitored during chemotherapy. Blossom Damania and Dirk Dittmer lead research on Kaposi sarcoma herpesvirus and virus-associated cancers.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/UNC_Lineberger_Comprehensive_Cancer_Center","links":[{"label":"UNC Lineberger","url":"https://unclineberger.org"},{"label":"Clinical trials","url":"https://unclineberger.org/patientcare/clinical-trials/"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","kaposi-sarcoma","dlbcl"],"sections":[],"technologies":["car-t","cdk46-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":["pam50"],"trials":[],"people":["charles-perou","ethan-basch"],"bottlenecks":["b-patient-voice","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chapel Hill, NC","country":"US","lat":35.905,"lng":-79.053,"institutionType":"cancer-center","website":"https://unclineberger.org","nci":"comprehensive","university":"University of North Carolina at Chapel Hill","programs":["Breast cancer subtyping (PAM50)","Academic CAR-T","Patient-reported outcomes","Viral oncology"]},"route":"/institutions/unc-lineberger/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/"}],"person":[{"id":"charles-perou","kind":"person","name":"Charles M. Perou","route":"/people/charles-perou/"},{"id":"ethan-basch","kind":"person","name":"Ethan Basch","route":"/people/ethan-basch/"},{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/"}],"bottleneck":[{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"paper":[{"id":"paper-perou-molecular-portraits-breast-tumours-nature-2000","kind":"paper","name":"Molecular portraits of human breast tumours","route":"/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/"},{"id":"paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020","kind":"paper","name":"Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","route":"/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/"},{"id":"paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006","kind":"paper","name":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","route":"/key-papers/paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006/"},{"id":"paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015","kind":"paper","name":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}